• Je něco špatně v tomto záznamu ?

Clinical and genetic determinants of chronic visual pathway changes after methanol - induced optic neuropathy: four-year follow-up study

O. Nurieva, JA. Hubacek, P. Urban, J. Hlusicka, P. Diblik, P. Kuthan, P. Sklenka, M. Meliska, J. Bydzovsky, J. Heissigerova, K. Kotikova, T. Navratil, M. Komarc, Z. Seidl, M. Vaneckova, L. Vojtova, S. Zakharov,

. 2019 ; 57 (6) : 387-397. [pub] 20181117

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc20006724

Grantová podpora
NV16-27075A MZ0 CEP - Centrální evidence projektů

CONTEXT: Methanol poisoning induces acute optic neuropathy with possible long-term visual damage. OBJECTIVE: To study the dynamics and key determinants of visual pathway functional changes during 4 years after acute methanol poisoning. METHODS: A total of 42 patients with confirmed methanol poisoning (mean age 45.7 ± 4.4 years) were examined 4.9 ± 0.6, 25.0 ± 0.6, and 49.9 ± 0.5 months after discharge. The following tests were performed: visual evoked potential (VEP), retinal nerve fiber layer (RNFL) measurement, brain magnetic resonance imaging (MRI), complete ocular examination, biochemical tests, and apolipoprotein E (ApoE) genotyping. RESULTS: Abnormal VEP P1 latency was registered in 18/42 right eyes (OD) and 21/42 left eyes (OS), abnormal N1P1 amplitude in 10/42 OD and OS. Mean P1 latency shortening during the follow-up was 15.0 ± 2.0 ms for 36/42 (86%) OD and 14.9 ± 2.4 ms for 35/42 (83%) OS, with maximum shortening up to 35.0 ms. No significant change of mean N1P1 amplitude was registered during follow-up. A further decrease in N1P1 amplitude ≥1.0 mcV in at least one eye was observed in 17 of 36 patients (47%) with measurable amplitude (mean decrease -1.11 ± 0.83 (OD)/-2.37 ± 0.66 (OS) mcV versus -0.06 ± 0.56 (OD)/-0.83 ± 0.64 (OS) mcV in the study population; both p < .001). ApoE4 allele carriers had lower global and temporal RNFL thickness and longer initial P1 latency compared to the non-carriers (all p < .05). The odds ratio for abnormal visual function was 8.92 (3.00-36.50; 95%CI) for ApoE4 allele carriers (p < .001). The presence of ApoE4 allele was further associated with brain necrotic lesions (r = 0.384; p = .013) and brain hemorrhages (r = 0.395; p = .011). CONCLUSIONS: Improvement of optic nerve conductivity occurred in more than 80% of patients, but evoked potential amplitude tended to decrease during the 4 years of observation. ApoE4 allele carriers demonstrated lower RNFL thickness, longer P1 latency, and more frequent methanol-induced brain damage compared to non-carriers.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20006724
003      
CZ-PrNML
005      
20220210092119.0
007      
ta
008      
200511s2019 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1080/15563650.2018.1532083 $2 doi
035    __
$a (PubMed)30451020
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Nurieva, Olga $u a Toxicological Information Centre, Department of Occupational Medicine, First Faculty of Medicine , Charles University and General University Hospital , Prague , Czech Republic.
245    10
$a Clinical and genetic determinants of chronic visual pathway changes after methanol - induced optic neuropathy: four-year follow-up study / $c O. Nurieva, JA. Hubacek, P. Urban, J. Hlusicka, P. Diblik, P. Kuthan, P. Sklenka, M. Meliska, J. Bydzovsky, J. Heissigerova, K. Kotikova, T. Navratil, M. Komarc, Z. Seidl, M. Vaneckova, L. Vojtova, S. Zakharov,
520    9_
$a CONTEXT: Methanol poisoning induces acute optic neuropathy with possible long-term visual damage. OBJECTIVE: To study the dynamics and key determinants of visual pathway functional changes during 4 years after acute methanol poisoning. METHODS: A total of 42 patients with confirmed methanol poisoning (mean age 45.7 ± 4.4 years) were examined 4.9 ± 0.6, 25.0 ± 0.6, and 49.9 ± 0.5 months after discharge. The following tests were performed: visual evoked potential (VEP), retinal nerve fiber layer (RNFL) measurement, brain magnetic resonance imaging (MRI), complete ocular examination, biochemical tests, and apolipoprotein E (ApoE) genotyping. RESULTS: Abnormal VEP P1 latency was registered in 18/42 right eyes (OD) and 21/42 left eyes (OS), abnormal N1P1 amplitude in 10/42 OD and OS. Mean P1 latency shortening during the follow-up was 15.0 ± 2.0 ms for 36/42 (86%) OD and 14.9 ± 2.4 ms for 35/42 (83%) OS, with maximum shortening up to 35.0 ms. No significant change of mean N1P1 amplitude was registered during follow-up. A further decrease in N1P1 amplitude ≥1.0 mcV in at least one eye was observed in 17 of 36 patients (47%) with measurable amplitude (mean decrease -1.11 ± 0.83 (OD)/-2.37 ± 0.66 (OS) mcV versus -0.06 ± 0.56 (OD)/-0.83 ± 0.64 (OS) mcV in the study population; both p < .001). ApoE4 allele carriers had lower global and temporal RNFL thickness and longer initial P1 latency compared to the non-carriers (all p < .05). The odds ratio for abnormal visual function was 8.92 (3.00-36.50; 95%CI) for ApoE4 allele carriers (p < .001). The presence of ApoE4 allele was further associated with brain necrotic lesions (r = 0.384; p = .013) and brain hemorrhages (r = 0.395; p = .011). CONCLUSIONS: Improvement of optic nerve conductivity occurred in more than 80% of patients, but evoked potential amplitude tended to decrease during the 4 years of observation. ApoE4 allele carriers demonstrated lower RNFL thickness, longer P1 latency, and more frequent methanol-induced brain damage compared to non-carriers.
650    _2
$a dospělí $7 D000328
650    _2
$a apolipoprotein E4 $x genetika $7 D053327
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a zrakové evokované potenciály $7 D005074
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a frekvence genu $7 D005787
650    _2
$a genetická predispozice k nemoci $7 D020022
650    _2
$a lidé $7 D006801
650    _2
$a longitudinální studie $7 D008137
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a methanol $x otrava $7 D000432
650    _2
$a lidé středního věku $7 D008875
650    _2
$a nervus opticus $x účinky léků $x patofyziologie $7 D009900
650    _2
$a nemoci zrakového nervu $x chemicky indukované $x diagnóza $x genetika $x patofyziologie $7 D009901
650    _2
$a prognóza $7 D011379
650    _2
$a prospektivní studie $7 D011446
650    _2
$a reakční čas $7 D011930
650    _2
$a rizikové faktory $7 D012307
650    _2
$a časové faktory $7 D013997
650    _2
$a poruchy zraku $x chemicky indukované $x diagnóza $x genetika $x patofyziologie $7 D014786
650    _2
$a zrak $x účinky léků $x genetika $7 D014785
651    _2
$a Česká republika $7 D018153
655    _2
$a časopisecké články $7 D016428
700    1_
$a Hubacek, Jaroslav A $u b Center for Experimental Medicine , Institute for Clinical and Experimental Medicine , Prague , Czech Republic.
700    1_
$a Urban, Pavel $u a Toxicological Information Centre, Department of Occupational Medicine, First Faculty of Medicine , Charles University and General University Hospital , Prague , Czech Republic. c Centre for Industrial Hygiene and Occupational Medicine , National Institute of Public Health , Prague , Czech Republic.
700    1_
$a Hlusicka, Jiri $u a Toxicological Information Centre, Department of Occupational Medicine, First Faculty of Medicine , Charles University and General University Hospital , Prague , Czech Republic.
700    1_
$a Diblik, Pavel $u d Clinic of Ophthalmology, First Faculty of Medicine , Charles University and General University Hospital , Prague , Czech Republic.
700    1_
$a Kuthan, Pavel $u d Clinic of Ophthalmology, First Faculty of Medicine , Charles University and General University Hospital , Prague , Czech Republic.
700    1_
$a Sklenka, Petr $u d Clinic of Ophthalmology, First Faculty of Medicine , Charles University and General University Hospital , Prague , Czech Republic.
700    1_
$a Meliska, Martin $u d Clinic of Ophthalmology, First Faculty of Medicine , Charles University and General University Hospital , Prague , Czech Republic.
700    1_
$a Bydzovsky, Jan $u d Clinic of Ophthalmology, First Faculty of Medicine , Charles University and General University Hospital , Prague , Czech Republic.
700    1_
$a Heissigerova, Jarmila $u d Clinic of Ophthalmology, First Faculty of Medicine , Charles University and General University Hospital , Prague , Czech Republic.
700    1_
$a Kotíková, Kateřina $u a Toxicological Information Centre, Department of Occupational Medicine, First Faculty of Medicine , Charles University and General University Hospital , Prague , Czech Republic. $7 xx0269332
700    1_
$a Navratil, Tomas $u e Department of Biomimetic Electrochemistry , J. Heyrovský Institute of Physical Chemistry of the Czech Academy of Sciences , Prague , Czech Republic. f Institute of Medical Biochemistry and Laboratory Medicine, First Faculty of Medicine , Charles University and General University Hospital in Prague , Prague , Czech Republic.
700    1_
$a Komarc, Martin $u g Department of Methodology, Faculty of Physical Education and Sport , Charles University , Prague , Czech Republic.
700    1_
$a Seidl, Zdenek $u h Department of Radiology, First Faculty of Medicine , Charles University in Prague and General University Hospital , Prague , Czech Republic.
700    1_
$a Vaneckova, Manuela $u h Department of Radiology, First Faculty of Medicine , Charles University in Prague and General University Hospital , Prague , Czech Republic.
700    1_
$a Vojtova, Lucie $u i First Faculty of Medicine, Institute of Clinical Biochemistry and Laboratory Diagnostics , Charles University and General University Hospital , Prague , Czech Republic.
700    1_
$a Zakharov, Sergey $u a Toxicological Information Centre, Department of Occupational Medicine, First Faculty of Medicine , Charles University and General University Hospital , Prague , Czech Republic.
773    0_
$w MED00013938 $t Clinical toxicology (Philadelphia, Pa.) $x 1556-9519 $g Roč. 57, č. 6 (2019), s. 387-397
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30451020 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200511 $b ABA008
991    __
$a 20220210092113 $b ABA008
999    __
$a ok $b bmc $g 1525582 $s 1096780
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 57 $c 6 $d 387-397 $e 20181117 $i 1556-9519 $m Clinical toxicology $n Clin Toxicol (Phila) $x MED00013938
GRA    __
$a NV16-27075A $p MZ0
LZP    __
$a Pubmed-20200511

Najít záznam

Citační ukazatele

Možnosti archivace